An illustration of one method of packaging and labeling of 
recombinant DNA-containing microorganisms and viral genomes 
defined as etiologic agents in the Preamble is shown in Figures 
1, 2, and 3. Additional information on packaging and shipment is 
given in the "Laboratory Safety Monograph--A Supplement to the 
NIH Guidelines for Recombinant DNA Research," available from the 
Office of Recombinant DNA Activities, and in the Biosafety in 
Microbiological and Biomedical Laboratories 1 . 
"Appendix H-II- — Footnotes and References of Appendix H: 
biosafety in Microbiological and Biomedical Laboratories, 2nd 
Edition, (May 1988), U.S. Department of Health and Human 
Services, Centers for Disease Control, Atlanta, Georgia 30333, 
and National Institutes of Health, Bethesda, Maryland 20892." 
Mr. Brewer asked if recombinant DNA products requiring biosafety 
level 1 containment would be exempt from the NIH Guidelines 
regarding shipping or if the proposal would encourage such an 
elimination. Dr. Langston believed that it might encourage such an 
elimination. She returned to the G-III-2 reference, suggesting 
that the proposal could be amended to "and/or contained." 
Otherwise, it would sound like the original Appendix B. Dr. Atlas 
added her suggestion to the proposal. 
Mr. Brewer, noting that time was running out, stated that the 
question should now be put to a vote, with the understanding that 
the draft proposal would have to be put into final form before 
being formally submitted to the RAC. Approval would therefore be 
conditional; if substantial disagreement arose, the proposal would 
not be submitted to the full RAC. Dr. McKinney suggested that the 
proposal, if approved, should instead go to the RAC as a working 
document and that comments could be made through the Federal 
Register publication process. The Subcommittee should not worry 
about fine-tuning. Mr. Brewer agreed. 
Mr. Brewer entertained a motion on the language as proposed by Dr. 
Atlas and amended through discussion. Dr. McKinney moved that the 
Subcommittee vote on the language. Dr. Langston seconded the 
motion. The proposal was approved by a vote of 7 in favor, 0 
opposed, and 0 abstained. 
Mr. Brewer adjourned the meeting at 12:00 p.m. 
[Executive Secretary note: Dr. Robert McKinney and Mr. Robert J. 
Crawford met after the meeting to develop the following paragraph 
for the illustration on shipping methods of etiologic agents: 
"Figures 1, 2, and 3 depict one method for the packaging and 
labeling of those recombinant DNA-containing organisms and viral 
genomes defined as etiologic agents in the Preamble of Appendix 
H. The key features are identified in Figure 1. It is the 
responsibility of the shipper to comply with the applicable 
requirements of 42 CFR part 72 and 49 CFR part 173 when shipping 
[298] 
Recombinant DNA Research, Volume 13 
